$ACHV

H.C. Wainwright reiterated a Buy rating and $12.00 price target for Achieve Life Sciences (ACHV) after 52-week ORCA-OL study data showed 31% of patients achieved smoking abstinence. The stock is up 57% in six months, trading at $6.50. Analysts expect a 2026 NDA resubmission and 2027 approval. ACHV appointed Benjamin Halladay as CFO, with Stifel and Morgan Stanley also initiating coverage with Buy ratings and targets of $18.00 and $13.00, respectively.

Achieve Life Sciences reported 52-week open-label results for cytisinicline, showing 31.2% sustained abstinence at Weeks 49–52, with 39.4% for prior-placebo participants. The Data Safety Monitoring Committee noted no new safety signals. The results support long-term efficacy and safety, according to the company.

Achieve Life Sciences granted its CFO, Benjamin Halladay, 200,000 stock options and 200,000 restricted stock units (RSUs). The options have a $7.01 exercise price and expire in 2036, vesting over four years. The RSUs vest annually from 2027 to 2030. Both awards are contingent on Halladay's continued service.

Achieve Life Sciences (ACHV) granted stock options and RSUs to new hires, including 200,000 shares each to its new CFO. The awards vest over four years. Achieve is developing cytisinicline for nicotine dependence, with an NDA supported by Phase 3 studies and Breakthrough Therapy designation for vaping cessation.

ACHIEVE LIFE SCIENCES, INC. (ACHV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 1, 2026, Achieve Life Sciences, Inc. (the “ Company ”) announced that the Board of Directors of the Company (th

Achieve Life Sciences (ACHV) named Benjamin Halladay as CFO, starting October 5, 2026. He previously served as CFO at Esperion Therapeutics from 2022 to 2026.

Stifel initiated Achieve Life Sciences (ACHV) with a Buy rating, citing the potential of its smoking cessation drug cytisinicline. The firm set a $ price target, implying 134% upside from the September 29 close, according to analyst James Condulis.

Achieve Life (ACHV) director Richard Alistair Stewart sold 20,626 shares at an average price of $8.493, retaining 208,249 shares directly and 1,241 indirectly. The sale occurred on August 19, 2026, with prices ranging from $8.4536 to $8.52 per share.

Stewart Richard Alistair sold 20,626 shares of ACHIEVE LIFE SCIENCES, INC. (ACHV) at $8.49 ($0.18M total) on 2026-08-19.

Achieve Life Sciences (ACHV) reported that Logos Global Management LP and related funds filed a Schedule 13G showing passive beneficial ownership of 10,538,440 shares, or 9.99% of the class, based on 102,902,490 shares outstanding as of Aug. 11, 2026. Holdings include 6,951,032 shares, options for 1,000,000 shares, and warrants for 2,751,032 shares.